| Literature DB >> 25602963 |
G P Rubin1, C L Saunders2, G A Abel2, S McPhail3, G Lyratzopoulos2, R D Neal4.
Abstract
BACKGROUND: For patients with symptoms of possible cancer who do not fulfil the criteria for urgent referral, initial investigation in primary care has been advocated in the United Kingdom and supported by additional resources. The consequence of this strategy for the timeliness of diagnosis is unknown.Entities:
Mesh:
Year: 2015 PMID: 25602963 PMCID: PMC4333492 DOI: 10.1038/bjc.2014.634
Source DB: PubMed Journal: Br J Cancer ISSN: 0007-0920 Impact factor: 7.640
Figure 1Flow diagram: derivation of the analysis sample.
Patient characteristics, mean and median (percentile) primary-care interval
| | | |||||
|---|---|---|---|---|---|---|
| 5036 | 32.5 | 8 | 0 | 34 | 87 | |
| Female | 2413 | 33.1 | 9 | 0 | 36 | 88 |
| Male | 2623 | 31.9 | 8 | 0 | 32 | 85 |
| 15–44 | 150 | 36.9 | 7.5 | 0 | 43 | 113 |
| 45–54 | 405 | 30.3 | 8 | 0 | 34 | 75 |
| 55–64 | 1030 | 31.1 | 8 | 0 | 33 | 85 |
| 65–74 | 1503 | 32.0 | 8 | 0 | 34 | 83 |
| 75–84 | 1430 | 33.6 | 9 | 0 | 36 | 88 |
| 85+ | 518 | 34.2 | 7 | 0 | 32 | 100 |
| Colorectal | 2111 | 33.0 | 6 | 0 | 30 | 94 |
| Ovarian | 345 | 21.5 | 7 | 0 | 25 | 54 |
| Lung | 1494 | 34.5 | 13 | 3 | 39 | 83 |
| Oesophageal | 513 | 26.3 | 6 | 0 | 31 | 75 |
| Pancreatic | 327 | 33.0 | 7 | 0 | 32 | 96 |
| Stomach | 246 | 43.2 | 13 | 0 | 58 | 132 |
| No | 1838 | 17.4 | 0 | 0 | 10 | 44 |
| Yes | 3198 | 41.2 | 16 | 5 | 45 | 106 |
Primary-care investigations and primary-care interval, by cancer
| | | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any investigation in primary care | No | 1838 | 17.4 | 0 | 967 | 18.6 | 0 | 105 | 7.5 | 0 | 294 | 17.1 | 1 | 293 | 15.5 | 0 | 81 | 15.5 | 0 | 98 | 24.9 | 0 |
| | Yes | 3198 | 41.2 | 16 | 1144 | 45.3 | 17 | 240 | 27.7 | 13 | 1200 | 38.9 | 16 | 220 | 40.7 | 21 | 246 | 38.8 | 13 | 148 | 55.3 | 22 |
| Blood test | No | 2996 | 26.3 | 4 | 1140 | 23.4 | 1 | 195 | 19.5 | 2 | 1058 | 32.6 | 11 | 350 | 19.4 | 1 | 122 | 23 | 0 | 131 | 32.7 | 2 |
| | Yes | 2040 | 41.6 | 15 | 971 | 44.4 | 16 | 150 | 24.1 | 13 | 436 | 39.5 | 17 | 163 | 41.2 | 21 | 205 | 39 | 12 | 115 | 55.2 | 21 |
| Chest X-ray | No | 3908 | 31.4 | 6 | 2070 | 33 | 6 | 327 | 21.1 | 7 | 464 | 31.9 | 7 | 494 | 25.9 | 4 | 314 | 31.5 | 7 | 239 | 42.8 | 12 |
| | Yes | 1128 | 36.2 | 16 | 41 | 36.3 | 12 | 18 | 29.2 | 15.5 | 1030 | 35.8 | 15 | 19 | 37 | 27 | 13 | 68.9 | 39 | 7 | 56.6 | 19 |
| Ultrasound | No | 4546 | 30.9 | 7 | 1979 | 31.8 | 5 | 186 | 14.4 | 2 | 1455 | 34.3 | 13 | 497 | 25.3 | 5 | 211 | 20.8 | 3 | 218 | 35.7 | 9 |
| | Yes | 490 | 47.7 | 20 | 132 | 50.8 | 21.5 | 159 | 29.9 | 14 | 39 | 44.3 | 22 | 16 | 56.8 | 33 | 116 | 55.3 | 21 | 28 | 101.5 | 57 |
| CT/MRI | No | 4928 | 31.9 | 8 | 2094 | 32.5 | 6 | 338 | 20.9 | 7 | 1420 | 33.6 | 12 | 511 | 26.3 | 6 | 320 | 33.2 | 7 | 245 | 43.4 | 13 |
| | Yes | 108 | 56.9 | 35 | 17 | 95.1 | 39 | 7 | 54.1 | 34 | 74 | 52.9 | 35 | 2 | 20.5 | 20.5 | 7 | 26 | 13 | 1 | 5 | 5 |
| Endoscopy | No | 4861 | 31.4 | 8 | 2022 | 31.1 | 5 | 341 | 21.7 | 7 | 1484 | 34.4 | 13 | 478 | 25.1 | 5 | 314 | 30.8 | 7 | 222 | 43.5 | 12 |
| | Yes | 175 | 63.1 | 20 | 89 | 76.7 | 20 | 4 | 7.5 | 7.5 | 10 | 56.4 | 40.5 | 35 | 43.2 | 15 | 13 | 86.7 | 49 | 24 | 40.5 | 19.5 |
| Count of any of the above five investigations | 0 | 1952 | 19.5 | 0 | 1031 | 20 | 0 | 108 | 8.3 | 0 | 312 | 22.4 | 2 | 315 | 17.7 | 0 | 82 | 15.9 | 0 | 104 | 25.9 | 0.5 |
| 1 | 2301 | 38.7 | 14 | 923 | 42.4 | 14 | 147 | 30.1 | 11 | 809 | 37.7 | 14 | 162 | 37.3 | 15 | 148 | 22.9 | 7.5 | 112 | 49.4 | 23 | |
| 2+ | 783 | 46.9 | 21 | 157 | 63.9 | 23 | 90 | 23.3 | 14 | 373 | 38.1 | 20 | 36 | 52.1 | 32.5 | 97 | 63 | 22 | 30 | 79.8 | 21 | |
Abbreviations: CT=computed tomography; MRI=magnetic resonance tomography.
The numbers in these two groups are slightly different as the first two rows include patients who have had any investigation in primary care, but the bottom three rows are counts based only on the five listed investigations (blood tests, chest X-rays, ultrasound, CT/MRI, or endoscopy).
Use of primary-care investigations and the NICE guideline referral category based on clinical presentation, by cancer
| | | | ||
|---|---|---|---|---|
| Colorectal | Mandated referral under NICE guidelines (or good clinical practice) | 208 | 99 | 47.6 |
| Possible referral under NICE guidelines | 1105 | 581 | 52.6 | |
| Mandated investigation under NICE guidelines | 200 | 90 | 45.0 | |
| Possible investigation under NICE guidelines | 0 | |||
| | No action under NICE guidelines | 598 | 374 | 62.5 |
| Ovarian | Mandated referral under NICE guidelines (or good clinical practice) | 31 | 12 | 38.7 |
| Possible referral under NICE guidelines | 5 | 0 | ||
| Mandated investigation under NICE guidelines | 26 | 16 | 61.5 | |
| Possible investigation under NICE guidelines | 0 | |||
| | No action under NICE guidelines | 283 | 212 | 74.9 |
| Lung | Mandated referral under NICE guidelines (or good clinical practice) | 76 | 39 | 51.3 |
| Possible referral under NICE guidelines | 0 | |||
| Mandated investigation under NICE guidelines | 223 | 195 | 87.4 | |
| Possible investigation under NICE guidelines | 916 | 779 | 85.0 | |
| | No action under NICE guidelines | 279 | 187 | 67.0 |
| Oesophageal | Mandated referral under NICE guidelines (or good clinical practice) | 328 | 121 | 36.9 |
| Possible referral under NICE guidelines | 9 | 0 | 0.0 | |
| Mandated investigation under NICE guidelines | 0 | |||
| Possible investigation under NICE guidelines | 69 | 36 | 52.2 | |
| | No action under NICE guidelines | 107 | 63 | 58.9 |
| Pancreatic | Mandated referral under NICE guidelines (or good clinical practice) | 79 | 59 | 74.7 |
| Possible referral under NICE guidelines | 100 | 65 | 65.0 | |
| Mandated investigation under NICE guidelines | 0 | |||
| Possible investigation under NICE guidelines | 0 | |||
| | No action under NICE guidelines | 148 | 122 | 82.4 |
| Stomach | Mandated referral under NICE guidelines (or good clinical practice) | 92 | 45 | 48.9 |
| Possible referral under NICE guidelines | 21 | 15 | 71.4 | |
| Mandated investigation under NICE guidelines | 0 | |||
| Possible investigation under NICE guidelines | 40 | 26 | 65.0 | |
| No action under NICE guidelines | 93 | 62 | 66.7 | |
Abbreviations: GP=general practitioner; NICE=National Institute for Health and Care Excellence.
Mean additional length of primary-care interval associated with primary-care investigations after adjustment for age, sex and NICE guideline referral category
| | | | | ||
|---|---|---|---|---|---|
| Colorectal | Not investigated | 967 | Reference | Reference | |
| | Investigated | 1144 | 26.7 (20.8–33.0) | 25.7 (19.5–31.7) | |
| Ovarian | Not investigated | 105 | Reference | Reference | |
| | Investigated | 240 | 20.1 (13.6–27.5) | 18.4 (12.2–25.5) | |
| Lung | Not investigated | 294 | Reference | Reference | |
| | Investigated | 1200 | 21.8 (15.3–27.6) | 23.6 (16.8–30.0) | |
| Oesophageal | Not investigated | 293 | Reference | Reference | |
| | Investigated | 220 | 25.3 (16.7–34.8) | 22.3 (13.2–32.4) | |
| Pancreaticc | Not investigated | 81 | Reference | Reference | |
| | Investigated | 246 | 23.2 (5.0–38.1) | 17.1 (−1.9–30.6) | |
| Stomach | Not investigated | 98 | Reference | Reference | |
| Investigated | 148 | 30.4 (15.1–48.2) | 29.3 (14.0–45.8) | ||
Abbreviation: NICE=National Institute for Health and Care Excellence.
95% Confidence intervals were estimated using bias corrected and accelerated bootstrap. The P-value (P>0.05) presented for pancreatic cancer reflects that this 95% confidence interval crosses zero. For all other cancers bias corrected and accelerated bootstrap 99.99%confidence intervals were re-estimated for the same model and these also did not cross zero, P<0.0001 is correspondingly presented.
‘Possible referrals' grouped with ‘No action' in multivariable analysis because of small numbers.
Age 15–44 years grouped with age 55–64 years because of small numbers.
Symptom groups by cancer
| Dysphagia | Haemoptysis | Ultrasound suggestive of ovarian cancer | Rectal bleeding | Obstructive jaundice |
| Early satiety | Chest/shoulder pain | Post-menopausal bleeding | Altered bowel habit (to looser stool) | Thromboembolic disease |
| Nausea, vomiting | Dyspnoea | Persistent intermenstrual bleeding (with a negative pelvic examination) | Abdominal mass | Bleeding per rectum/melaena |
| Dyspepsia | Weight loss | Abdominal or pelvic mass not of gastroenterological or urological origin | Rectal mass | Diabetic ketoacidosis/new onset diabetes/loss of known diabetes control |
| Reflux | Chest signs | Abdominal or pelvic pain or discomfort | Anaemia | Altered bowel habit |
| Pain (epigastric, abdominal, chest) | Hoarseness | Abdominal bloating/distension/swelling/fullness | Weight loss | Nausea and vomiting |
| Anorexia | Clubbing | Urinary symptoms (including incontinence and retention) | Abdominal pain or tenderness | Gastro-oesophageal reflux disease |
| Fatigue, malaise | Chest X-ray/supraclavicular lymph nodes | Unexplained weight loss | Bloating/distension | General malaise |
| Weight loss | Cough | Fatigue/tiredness/malaise/unwell/exhaustion | Malaise | Bloating |
| Bowel disturbance | Features suggesting metastases | Change in bowel habit to diarrhoea or alternating diarrhoea/constipation | Asymptomatic or incidental, including surveillance | Biliary colic |
| Iron deficiency anaemia | Abnormal chest X-ray | | Acute surgical/medical emergency | Cough/shortness of breath |
| Haematemesis/melaena | Superior vena cava obstruction | Vaginal discharge or other abnormal vaginal bleeding | Constipation | Weight loss |
| Dizziness | Stridor | Anaemia | Nausea/vomiting | Urinary tract infection/other urinary symptoms |
| Upper abdominal mass | Loss of appetite | Chest symptoms | Other pain | anaemia |
| Asymptomatic or incidental finding | Thrombocytosis | Pulmonary embolus or deep vein thrombosis | Defaecation problems | Back pain |
| Pain (other) | Abnormal spirometry | Infertility | Anorexia | Abdominal pain |
| Barrett's | Asymptomatic or incidental | Nausea and/or vomiting | Mucus | Abdominal mass |
| Respiratory symptoms | Hyponatraemia | Asymptomatic or incidental | Collapse | Asymptomatic or incidental |
| Bloating | Respiratory infection | Ascites | Respiratory symptoms | Anorexia |
| Belching | Exacerbation of chronic obstructive pulmonary disease | Anorexia | Haemorrhoids | Dysphagia |
| Throat symptoms | Abdominal pain | Other/missing/not stated/not known | Urinary symptoms | Change in bowel habit |
| Hiatus hernia | Back pain | | Liver | Dyspepsia |
| Odynophagia | Liver symptoms/signs | | Upper gastrointestinal symptoms | |
| Other/missing/not stated/not known | Confusion | | Disordered sensation lower limbs | Liver |
| | Malaise | | Ascites | Pancreatitis/chronic |
| | Collapse | | Colitis/inflammatory bowel disease | Steatorrhoea |
| | Change in bowel habit | | Other/missing/not stated/not known | Lymphadenopathy |
| | Pain (other) | | | Other/missing/not stated/not known |
| | Urinary symptoms | | | |
| | Headache | | | |
| | Lower limb oedema | | | |
| | Sweats/fever | | | |
| | Anaemia | | | |
| | Upper gastrointestinal symptoms | | | |
| | Lump | | | |
| | Nausea or vomiting | | | |
| | Cardiac abnormalities | | | |
| | Neurological | | | |
| | ENT symptoms | | | |
| Other/missing/not stated/not known |
Abbreviation: ENT=ear, nose and throat.
NICE guideline referral categories based on clinical presentation
| Mandated referral under NICE guidelines (or good clinical practice) | Clear evidence for mandated urgent referral as per NICE CG27 |
| Good clinical medicine would mandate urgent referral | |
| Possible referral under NICE guidelines | Possible mandated urgent referral as per NICE CG27—but duration dependent |
| Possible mandated urgent referral as per NICE CG27—but severity dependent | |
| Possible mandated urgent referral as per NICE CG27—but location dependent | |
| Possible mandated urgent referral as per NICE CG27—but dependent upon sense of abnormality | |
| | Possible mandated urgent referral as per NICE CG27—other |
| Mandated investigation under NICE guidelines | Clear evidence of mandated investigation as per NICE CG27 |
| Possible investigation under NICE guidelines | Possible mandated investigation as per NICE CG27—but duration dependent |
| Possible mandated investigation as per NICE CG27—but severity dependent | |
| Possible mandated investigation as per NICE CG27—but location dependent | |
| Possible mandated investigation as per NICE CG27—but dependent upon sense of abnormality | |
| | Possible mandated investigation as per NICE CG27—other |
| No action under NICE guidelines | No mandated action from NICE CG27 |
Abbreviation: NICE=National Institute for Health and Care Excellence.
Sensitivity analysis using alternative parameterisation of primary-care interval
| Colorectal | Not investigated | 967 | Reference | <0.001 | |
| | Investigated | 1144 | 4.6 (3.7–5.6) | | |
| Ovarian | Not investigated | 105 | Reference | <0.001 | |
| | Investigated | 240 | 4.2 (2.3–7.9) | | |
| Lung | Not investigated | 294 | Reference | <0.001 | |
| | Investigated | 1200 | 3.8 (2.8–5.2) | | |
| Oesophageal | Not investigated | 293 | Reference | <0.001 | |
| | Investigated | 220 | 4.1 (2.8–6.1) | | |
| Pancreatic | Not investigated | 81 | Reference | <0.001 | |
| | Investigated | 246 | 4.4 (2.1–9.2) | | |
| Stomach | Not investigated | 98 | Reference | <0.001 | |
| Investigated | 148 | 5.7 (3.1–10.6) |
Abbreviations: CI=confidence interval; NICE=National Institute for Health and Care Excellence; OR=odds ratio.
Results presented in bold italics are those from Table 4
This sensitivity analysis finds that investigation use is associated with longer primary-care interval for all six cancers when using a logistic model.
Sensitivity analysis using alternative parameterisation of investigation use in primary care
| Colorectal | Not investigateda | 967 | No investigationsa | 1031 | Reference | |
| Investigated | 1144 | One | 923 | 21.3 (15.1–30.0) | ||
| | | | | Two+ | 157 | 43.5 (28.3–58.2) |
| Ovarian | Not investigated | 105 | No investigations | 108 | Reference | |
| Investigated | 240 | One | 147 | 20.1 (11.0–30.6) | ||
| | | | | Two+ | 90 | 13.6 (6.0–21.2) |
| Lung | Not investigated | 294 | No investigations | 312 | Reference | |
| Investigated | 1200 | One | 809 | 17.0 (6.9–24.7) | ||
| | | | | Two+ | 373 | 16.2 (6.6–24.8) |
| Oesophageal | Not investigated | 293 | No investigations | 315 | Reference | |
| Investigated | 220 | One | 162 | 17.1 (7.7–28.8) | ||
| | | | | Two+ | 36 | 29.9 (10.3–58.1) |
| Pancreatic | Not investigated | 81 | No investigations | 82 | Reference | |
| Investigated | 246 | One | 148 | 4.8 (−14.4–16.7) | ||
| | | | | Two+ | 97 | 41.3 (20.2–62.5) |
| Stomach | Not investigated | 98 | No investigations | 104 | Reference | |
| Investigated | 148 | One | 112 | 21.2 (6.2–35.8) | ||
| Two+ | 30 | 56.0 (16.7–107.8) |
Abbreviations: CT=computed tomography; MRI=magnetic resonance tomography; NICE=National Institute for Health and Care Excellence.
aThe numbers in these two groups (for all cancers) are slightly different as column 3 includes patients who have had any investigation in primary care, but counts in column 6 are based only on the five listed investigations (blood tests, chest X-rays, ultrasound, CT/MRI, or endoscopy).
Results presented in bold italics are those from Table 4
With a single exception (pancreatic cancer) primary-care investigations were associated with longer primary-care intervals. For colorectal, oesophageal, pancreatic and stomach cancer, primary-care intervals were longer among people who had two or more primary-care investigations, compared with those who had one. For lung and ovarian cancer. investigation use was associated with longer primary-care interval, but delay was not additionally longer among people with two or more primary-care investigations, compared with only one.
Sensitivity analysis using alternative parameterisation of clinical presentation (symptom category) or the NICE referral category
| Colorectal | Not investigated | 967 | Reference | Reference | Reference | |
| | Investigated | 1144 | 24.6 | 26.5 | 26.2 | |
| Ovarian | Not investigated | 105 | Reference | Reference | Reference | |
| | Investigated | 240 | 18.5 | 17.8 | 18.1 | |
| Lung | Not investigated | 294 | Reference | Reference | Reference | |
| | Investigated | 1200 | 23.9 | 20.1 | 20.8 | |
| Oesophageal | Not investigated | 293 | Reference | Reference | Reference | |
| | Investigated | 220 | 22.7 | 23.4 | 23.0 | |
| Pancreatic | Not investigated | 81 | Reference | Reference | Reference | |
| | Investigated | 246 | 14.9 | 13.9 | 16.0 | |
| Stomach | Not investigated | 98 | Reference | Reference | Reference | |
| Investigated | 148 | 28.4 | 27.7 | 28.0 |
Abbreviation: NICE=National Institute for Health and Care Excellence.
Results presented in bold italics are those from Table 4.
Different approaches to adjusting for clinical presentation in different ways have minimal impact on the association between primary-care investigation use and primary-care interval.
Supplementary analysis. The association between investigation use and referral interval (defined as period from day of referral to day when patient was first seen at hospital)
| | | ||||||
|---|---|---|---|---|---|---|---|
| Colorectal | Not investigated | 946 | Reference | 946 | Reference | ||
| | Investigated | 1120 | 5.1 (2.1–8.7) | 1120 | 28.4 (21.9–34.9) | ||
| Ovarian | Not investigated | 101 | Reference | 101 | Reference | ||
| | Investigated | 236 | 1.6 (−5.0–4.6) | 238 | 18.7 (10.0–27.4) | ||
| Lung | Not investigated | 290 | Reference | 290 | Reference | ||
| | Investigated | 1165 | 4.5 (−1.6–10.1) | 1165 | 28.6 (19.4–36.8) | ||
| Oesophageal | Not investigated | 283 | Reference | 283 | Reference | ||
| | Investigated | 215 | 4.5 (−2.2–13.3) | 215 | 29.1 (18.2–42.5) | ||
| Pancreatic | Not investigated | 78 | Reference | 78 | Reference | ||
| | Investigated | 241 | −9.4 (−33.2–3.1) | 241 | 7.4 (−15.6–30.3) | ||
| Stomach | Not investigated | 95 | Reference | 95 | Reference | ||
| Investigated | 141 | 11.9 (5.1–26.7) | 141 | 41.8 (21.5–63.4) | |||
Abbreviation: NICE=National Institute for Health and Care Excellence.
Results presented in bold italics are those from Table 4.